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Eculizumab as rescue therapy in severe resistant
lupus nephritis
SIR, LN is a serious complication of SLE that can be re-
fractory to existing immunosuppressive treatment. We
present the clinical course of a patient with refractory LN
who was treated with eculizumab, a monoclonal anti-
complement C5 antibody therapy [1]. A Caucasian
female with SLE first presented with immune thrombocy-
topaenic purpura at the age of 14 years. Three years later
she developed polyarthralgia, oral ulcerations, RP, alope-
cia and pleurisy. Anti-nuclear and anti-dsDNA antibodies
were positive; C3 and C4 levels were reduced; antibodies
to extractable nuclear antigens and cardiolipin and LA
were all negative. The urine protein:creatinine ratio was
14 (normal <20 mg/mmol), serum creatinine 75 mmol/l
(normal range 60110) and albumin 36 g/l (normal range
3347). Disease control was achieved with prednisolone
and HCQ, but 2 years later she developed proteinuria
(protein:creatinine ratio 1123, albumin 27 g/l, creatinine
110mmol/l) and renal biopsy showed florid diffuse prolif-
erative GN, International Society of Nephrology/Renal
Pathology Society class IV-G (A) LN, with active lesions
in 10/10 glomeruli and crescents in 5/10 glomeruli. She
was treated with six i.v. 500-mg pulses of CYC, rituximab
infusions (two 1-g infusions 14 days apart) and then main-
tenance therapy with MMF. At 12 months she had partial
improvement (protein:creatinine ratio 240, albumin 29 g/l,
creatinine 92mmol/l), but at 15 months renal function dete-
riorated (protein:creatinine ratio 761, albumin 26 g/l, cre-
atinine 93 mmol/l) and repeat renal biopsy showed ongoing
active class IV LN. A further cycle of CYC and rituximab
was administered followed by tacrolimus monotherapy.
Over the course of the next 22 months, impaired renal
function persisted. A third renal biopsy, taken due to a
further deterioration in renal function (protein:creatinine
ratio 1082, albumin 27 g/l, creatinine 108 mmol/l), revealed
diffuse proliferative LN class IV-G (A/C). MMF was added,
but renal function continued to decline (protein:creatinine
ratio 2540, albumin 22 g/l, creatinine 211mmol/l) and a
fourth renal biopsy, 4 years after the first renal biopsy,
showed class IV-G (A/C) LN with active lesions in 20 out
of 36 glomeruli, chronic lesions in 7 out of 36 glomeruli,
acute tubular damage with foci of lymphocytic tubulitis
and marked chronic inflammatory interstitial infiltrate.
There was granular mesangial and capillary wall staining
for C9 consistent with activation of the complement ter-
minal pathway (Fig. 1A shows a representative glomerulus
with marked lobulation, mesangial proliferation, capillary
wall thickening and prominent endocapillary hypercellular-
ity with occlusion of capillary lumens. CD68 staining
shows several macrophages in the glomerulus). In view
of her previous poor response to CYC, rituximab, MMF
and tacrolimus, together with biopsy-proven evidence of
ongoing glomerular inflammation and complement C5 ac-
tivation, it was decided to administer a single i.v. methyl-
prednisolone 500-mg infusion, together with eculizumab.
She received four 1200-mg weekly eculizumab infusions
followed by two 1200-mg fortnightly infusions.
Complement haemolytic activity remained undetectable
following the first infusion and for 1 month after the sixth
infusion (Fig. 1B). Antibiotic prophylaxis was instigated
throughout the eculizumab treatment period. During and
following eculizumab treatment, there was a sustained
and rapid improvement in her renal function (Fig. 1C).
Following eculizumab therapy she was recommenced on
MMF. Renal biopsy, 18 months following eculizumab
treatment showed mesangial proliferation, capillary wall
thickening and segmental glomerulosclerosis, but no
endocapillary hypercellularity or necrosis, and C9 staining
was almost undetectable. Consistent with this, staining
for CD68, a macrophage marker, was markedly reduced
(Fig. 1A).
The current management of LN includes corticoster-
oids and cytotoxic agents such as CYC, MMF and
AZA, but there is increasing use of biologic therapy,
most commonly rituximab [2]. Complement activation is
common in lupus tissue injury [3], and blockade of com-
plement C5 has been shown to ameliorate murine SLE
[4]. Eculizumab is a recombinant fully humanized IgG2/
IgG4 monoclonal antibody that binds to complement
component C5 and prevents the cleavage of C5 and
therefore the formation of the anaphylatoxin C5a and
the membrane attack complex (C5b-9) [1]. Eculizumab
has efficacy in the prevention of red cell lysis in parox-
ysmal nocturnal haemoglobinuria [1] and in the treatment
of atypical haemolytic uraemic syndrome [5]. There have
been reports of its efficacy in C3 glomerulopathy [6], but
only one report of efficacy in LN [7]. However, in this
case, the renal pathology was thrombotic microangiopa-
thy (TMA), not GN. Efficacy has also been reported in
TMA in the setting of IgA nephropathy [8]. To our know-
ledge, there are no reports of the use of eculizumab to
treat non-TMA glomerular lesions in SLE. Our case indi-
cates that, in the right setting, eculizumab may have
therapeutic utility in LN. In a complex condition like LN,
patient stratification will be critical for rigorously evaluat-
ing the potential benefits of eculizumab. Two criteria,
which are not mutually exclusive, would include TMA
and reversible GN in which there is evidence of C5 acti-
vation within the kidney.
Rheumatology key message
. Lupus nephritis may respond to complement C5
inhibition.
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